||5U2CCA252981-02 Interpret this number
||Washington University Participant Engagement and Cancer Genomic Sequencing Center (Wu-Pe-Cgs)
Vision. Participant engagement and sequencing research from the Washington University Participant
Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge,
methodology, and characterization of understudied cancer populations, leading to optimal approaches to
participant engagement, outreach, and communication in genomic characterization studies.
Goal. The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches direct
engagement of cancer patients and post-treatment cancer survivors as participants in cancer research. Our
focus is on rare and understudied cancer populations with significant disparities including cholangiocarcinoma,
multiple myeloma, and colorectal cancer under age 50. Participant engagement strategies are most effective
when they are adapted and implemented in real-world settings in partnership with community and patient
Setting. Our Center will be housed in an exceptional environment that fosters transdisciplinary collaboration,
catalyzes new ideas in patient engagement, and ensures support for patient engagement and genome
sequencing that finds solutions for complex recruitment and engagement challenges in real-world settings with
underrepresented patient populations. Significant matching contributions from Washington University will allow
us to quickly and strategically invest in ideas.
Aims. The specific aims of the Center are to: (1) Advance the field of participant engagement to study cancer
disparities and rare cancers by conducting innovative and impactful direct stakeholder engagement with
continuous evaluation and research; (2) Expand an exceptional, diverse team of investigators, patients, and
advocacy stakeholders; (3) Address cancer disparities by understanding barriers to and improving the ability
for disadvantaged and understudied populations to encounter, use, and benefit from genomic sequencing and
analysis; (4) Organize and integrate Center units to facilitate transdisciplinary, team science within our Center
and across the PE-CGS Network.
Innovations and impact. The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer
disparities and genomic research across the cancer continuum. We will be particularly innovative and allow for
a significant return on the scientific investment in several ways. First, our Center has distinctive features that
include a combined focus on cancer disparities, the application of strategies to increase participant
engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise.
Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied
cancers. Third, we engage investigators from different disciplines and invest in the development of early
career scholars. Fourth, we will strategically and creatively disseminate products in ways that will benefit
researchers, practitioners, and community members. Fifth, we will partner with exceptional patient-centered
and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results.
Input from these groups, patients, and their families is a key strength that will leverage our track record of
stakeholder-engaged research. And finally, we have developed a focused strategy for collective integration of
our units. These synergies will allow our Center to become a national resource for optimal approaches to
participant engagement, outreach, and communication in genomic characterization studies and other studies
as technologies advance that will accelerate progress for both the scientific community, patients and their
In summary, we are uniquely situated to advance a network of participant engagement and sequencing
researchers, integrate research with patients and their stakeholders, build intellectual capital, and significantly
enhance the capacity for participant engagement and genomic characterization studies. This Center will
ultimately benefit health systems, providers, and people with rare cancers and lead to a reduction in cancer
Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
, Chaudhuri A.A.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022-02-20; 40(6), p. 567-575.